Quarterly report pursuant to Section 13 or 15(d)

Asset Acquisition - Narrative (Details)

v3.24.2
Asset Acquisition - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Mar. 28, 2024
Mar. 27, 2024
Apr. 30, 2024
Mar. 31, 2024
Private Placement        
Asset Acquisition, Contingent Consideration [Line Items]        
Preferred Stock, convertible, shares issuable in common stock (in shares)   1,000   1,000
AlmataBio Transaction        
Asset Acquisition, Contingent Consideration [Line Items]        
Common stock shares issued (in shares)   171,605    
Shares issuable in common stock (in shares)   2,412    
Payments to acquire productive assets $ 7,500     $ 7,500
AlmataBio Transaction | Subsequent Event        
Asset Acquisition, Contingent Consideration [Line Items]        
Payments to acquire productive assets     $ 7,500  
AlmataBio Transaction | Milestone One        
Asset Acquisition, Contingent Consideration [Line Items]        
Milestone payment due upon first patient dosed in a Phase 2 trial 5,000      
AlmataBio Transaction | Milestone Two        
Asset Acquisition, Contingent Consideration [Line Items]        
Milestone payment due upon first patient dosed in a Phase 2 trial $ 15,000